Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTA01 for Severe COVID-19 (MASP3)
NCT04683328Phase 3Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of upanovimab in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Status: unknown.
02
Drugs
upanovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04683328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683328.